<DOC>
	<DOCNO>NCT01228409</DOCNO>
	<brief_summary>Psoriasis chronic skin disorder prevalence approximately 1-3 % worldwide . At present , curative therapy available clinical course unpredictable , majority case psoriasis chronically remit relapse disease . Several clinical subtypes psoriasis exist difference manifestation skin area involve . Chronic stable plaque psoriasis ( Psoriasis Vulgaris ) common form disease , account 85-90 % case . The circumscribed infiltrate skin lesion scaly erythematous often symmetrically distribute body . Several type palliative therapy exist . The therapy either topical systemic . The severity chronic plaque psoriasis often determine percentage body surface area ( BSA ) involve . For mild , moderate severe chronic plaque psoriasis BSA involvement 20 % , initial therapy topical . Phototherapy numerous systemic therapy usually indicate 20 % skin affect . Severe plaque-type psoriasis require systemic long-term therapy order induce maintain remission . Acitretin 25mg/day combine phototherapy regimen standard treatment provide clinically significant efficacy , however many patient experience tolerability issue due retinoid-related adverse event . Retinoid-related adverse event include limited : alopecia , dry mucus membrane , pruritus , photosensitivity , elevation liver enzymes , elevation serum triglyceride , cholesterol decrease HDL , arthralgia , myalgia , eye irritation , blepharitis , photophobia , conjunctivitis , headache , nausea , anemia leukemia . Reducing acitretin dose 25mg/day 17.5mg/day may provide improved tolerability without compromise efficacy . The purpose study ascertain reduce acitretin dose 25mg/day 17.5mg/day provide improve tolerability without compromise efficacy .</brief_summary>
	<brief_title>Low-Dose ( 17.5 mg/Day ) Acitretin : Comparable Efficacy Without Side Effects ?</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>Male female subject 18 year age old . Surgically sterile female . Females hysterectomy oophorectomy complete menopause ( postmenopausal least 1 year ) allow . Men must agree use 2 form birth control ( eg condom , spermicide ) . Stabilized phototherapy regimen 4 week . Compliant acitretin dose 25 mg/day experience retinoidrelated adverse event , clinical judgement investigator , may benefit reduction dose 17.5 mg/day . Able complete study comply study instruction . Adherence alcohol avoidance acitretin therapy 2 month discontinuation acitretin . Subjects must willing donate blood study well 3 year follow completion study . Capable understanding willing provide sign dated write voluntary inform consent ( local national authorization requirement ) protocol specific procedure perform . Uncontrolled hypertriglyceridemia . Guttate , erythrodermic , pustular psoriasis . Severely impaired hepatic function , &gt; 3 time upper limit normal clinical investigator 's judgment . Use systemic immunosuppressant agent ( eg . Methotrexate , cyclosporine , thioguanine , azathioprine , alefacept , egalizumab , corticosteroid ) within 4 week baseline throughout study . Topical vitamin A , vitamin D analogue preparation , anthralin within 2 week study initiation . History know suspect intolerance ingredient investigational study product . Used counter ( nonprescription ) medication herbal remedy within 2 week dose , unless agree upon clinically relevant principal investigator . Participated previous study study product . Currently use medication , opinion investigator , may affect evaluation study product place subject undue risk . Currently suffer disease condition , opinion investigator , may affect evaluation study product place subject undue risk . Any major illness within 30 day screen examination . Considered immunocompromised . A clinically relevant history current evidence abuse alcohol drug . Use investigational drug treatment study within 4 week baseline visit . Women childbearing potential ( see inclusion criterion ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>phototherapy</keyword>
	<keyword>soriatane</keyword>
	<keyword>acitretin</keyword>
	<keyword>retinoid-related adverse event</keyword>
</DOC>